Dr. Axe Wire · Advanced therapies · health

Airway Cell Packets Calm Asthma Inflammation in Mice

Tiny cell-released packets carrying one microRNA blocked a key immune trap process that damages airways in asthmatic mice.

By Dr. Josh Axe · November 7, 2026 · 1 source · Watch

Photo: Pexels

A new mechanism for calming asthma-driven lung inflammation was published October 26, 2026 in Redox Biology, where researchers traced how a molecule released by airway cells can block a destructive immune process in mice with asthma.

Researchers used lab-grown human airway cells called BEAS-2B cells, isolating the tiny packets they release, known as exosomes, and tested them in neutrophils exposed to an inflammation-triggering chemical and in mice whose asthma-like airway inflammation was triggered by house dust mite allergen. The exosomes delivered a small genetic molecule called miR-146a-3p directly into neutrophils, the immune cells responsible for releasing sticky, web-like structures called neutrophil extracellular traps, or NETs, that the study describes as core drivers of allergic airway damage. The molecule worked by blocking a protein called HIF-1α from moving into the cell nucleus and activating a gene called ELANE, which produces an enzyme neutrophils need to build these traps. With that gene less active, NET release dropped.

Researchers also found that lowering NET release shifted activity in a cell-stress pathway called cGAS-STING and reversed abnormal levels of three proteins, GPX4, SLC7A11 and ACSL4, that control iron balance and a form of cell death called ferroptosis in airway cells. In plain terms, less debris from immune traps meant airway lining cells were better protected from a kind of self-destruction tied to iron buildup, and overall lung inflammation eased in the treated mice.

NETs act as core drivers of allergic asthma pathology by amplifying airway inflammation and inducing airway epithelial ferroptosis

Study authorsRedox Biology, 2026

This is animal and lab-dish evidence, not a human study, and sample sizes were not reported in the abstract. Whether this exosome-delivered molecule would work the same way, or be deliverable safely, in people with asthma is the logical next step to study.

Dr. Axe’s Take

Immune cells releasing sticky traps that injure the airway lining and push it toward iron-driven cell death is a compelling piece of the asthma puzzle, and blocking that process eased lung inflammation in these mice. For people managing asthma today, I would focus on cutting exposure to the triggers that drive this kind of immune response, dust mites, mold and poor indoor air quality, since reducing allergen exposure targets the same kind of trigger used in this mouse model. Keep taking any prescribed asthma medication exactly as directed, and talk with your doctor about your specific triggers and control plan.

— Dr. Axe

Take the Cellular Health Quiz →

Story summary

Who: Lab-grown human airway cells (BEAS-2B) and a mouse model of allergic asthma triggered by house dust mite allergen; sample sizes not reported.
Design: Neutrophils exposed to an inflammation-triggering chemical, plus mice with allergen-triggered asthma-like lung inflammation, testing exosomes carrying miR-146a-3p.
Dose: Not reported
Primary result: Exosomal miR-146a-3p blocked HIF-1α activity, reduced the neutrophil enzyme NE, and cut release of web-like immune traps (NETs) in neutrophils and asthmatic mice.
Secondary: Lower NETs shifted cGAS-STING signaling and reversed abnormal GPX4, SLC7A11 and ACSL4 levels, reducing airway epithelial ferroptosis and easing lung inflammation.
Funding / conflicts: Funders listed in the journal record: Jilin Provincial Science and Technology Department; The Education Department of Jilin Province; National Natural Science Foundation of China; Health Commission of Jilin Province. Competing interests: The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Date: Oct 26, 2026